In a recent paper in Traffic, Lene Malerød, a postdoc in Stenmark’s lab, shows that the ESCRT-II complex is required for degradation of ubiquitinated epidermal growth factor receptor and chemokine receptors. This provides new insight into how growth factor and chemokine receptors are transported intracellularly and identifies a novel potential tumour suppressor complex.
Binding of growth factors and cytokines to their cognate receptors on cell membranes triggers their endocytosis and degradation in lysosomes, thus providing a physiologically important negative feedback mechanism for cell signalling.
The ESCRT-II complex recognizes ubiquitinated receptors in the endosomal membrane, thus initiating their sorting to degradative lysosomes. (click to enlarge image)It is not known in detail how endocytosed receptors are trafficked to the degradative lysosomes, but work in Harald StenmarkÂ’s lab has uncovered several factors involved in this process. Among these are the so-called endosomal sorting complexes required for transport (ESCRTs), and Thomas Slagsvold in StenmarkÂ’s group has previously shown that the so-called GLUE domain in the ESCRT-II complex binds ubiquitin .
In a recent paper in Traffic, Lene Malerød, a postdoc in Stenmark’s lab, shows that the ESCRT-II complex is required for degradation of ubiquitinated epidermal growth factor receptor and chemokine receptors. This provides new insight into how growth factor and chemokine receptors are transported intracellularly and identifies a novel potential tumour suppressor complex.
From major journals, first or last author from the Institute for Cancer Research
Ghiasvand R(2026) High-Risk Stage II Melanoma: AJCC Staging anomaly or understaging dilemma? Br J Dermatol(in press) DOI 10.1093/bjd/ljaf523, PubMed 41483011
Unal B, Saatcioglu F(2025) Targeting the unfolded protein response for cancer therapy: mitigating tumor adaptation and immune suppression Biomark Res, 13(1), 156 DOI 10.1186/s40364-025-00813-y, PubMed 41372991
Pinto R, Sjurgard IV, Pharo H, Mala T, Vedeld HM, Lind GE(2025) Molecular stratification of esophageal adenocarcinoma: implications for prognosis and treatment strategy Oncogene(in press) DOI 10.1038/s41388-025-03650-3, PubMed 41361079
Wang X, Nguyen J, Nader K, Miihkinen M, Wall P, Singhal A, Bedard PL, Ideker T, Aittokallio T, Haibe-Kains B(2026) Discovery of predictive biomarkers for cancer therapy through computational approaches Nat Rev Clin Oncol(in press) DOI 10.1038/s41571-025-01109-8, PubMed 41495240
Kanetsky PA, Almstrup K, Cherlin S, Cortessis VK, Ferlin A, Gietema JA, González-Neira A, Grotmol T, Hamilton RJ, Haugen TB, Kiemeney LA, Kim J, Krausz C, Lessel D, Lothe RA, Nead KT, Nsengimana J, Poynter JN, Rajpert-DeMeyts E, Richiardi L, Schwartz SM, Skotheim RI, Stewart DR, Turnbull C, Wiklund Fet al.(2026) The Testicular Cancer Consortium (TECAC): Filling Knowledge Gaps in the Genetic Etiology of Testicular Germ Cell Tumors Andrology, e70168(in press) DOI 10.1111/andr.70168, PubMed 41486674